What is the P/E ratio of 2Seventy Bio 2025?
The P/E ratio cannot be calculated for 2Seventy Bio at the moment.
2Seventy Bio Stock TSVT
Price
Price
0
Today +/-
-0
Today %
-0 %
TickerTSVT
ISINUS9013841070
2Seventy Bio stock price
Loading chart...
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the 2Seventy Bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the 2Seventy Bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the 2Seventy Bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze 2Seventy Bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
2Seventy Bio Stock Price History
| Date | 2Seventy Bio Price |
|---|---|
| 5/12/2025 | 0 undefined |
| 5/12/2025 | 5.00 undefined |
| 5/9/2025 | 5.00 undefined |
2Seventy Bio Revenue, EBIT, Net Income
3 years
5 years
10 years
25 Years
Max
Loading chart...
Revenue
EBIT
Net Income
Details
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into 2Seventy Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by 2Seventy Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects 2Seventy Bio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of 2Seventy Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into 2Seventy Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing 2Seventy Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on 2Seventy Bio’s growth potential.
2Seventy Bio Revenue, EBIT and net profit per share
| Date | 2Seventy Bio Revenue | 2Seventy Bio EBIT | 2Seventy Bio Net Income |
|---|---|---|---|
| 2030e | 111.4 M undefined | 0 undefined | 47.4 M undefined |
| 2029e | 89.45 M undefined | 5 M undefined | 31.96 M undefined |
| 2028e | 85.8 M undefined | -6.94 M undefined | 21.84 M undefined |
| 2027e | 80.93 M undefined | 128,010 undefined | 14.38 M undefined |
| 2026e | 76.62 M undefined | -12.5 M undefined | -12.43 M undefined |
| 2025e | 69.85 M undefined | -32.64 M undefined | -24.32 M undefined |
| 2024 | 37.86 M undefined | -98.57 M undefined | -57.25 M undefined |
| 2023 | 100.39 M undefined | -216.94 M undefined | -217.57 M undefined |
| 2022 | 91.5 M undefined | -253.5 M undefined | -254.2 M undefined |
| 2021 | 54.5 M undefined | -303.8 M undefined | -292.2 M undefined |
| 2020 | 248.1 M undefined | -138.2 M undefined | -120.1 M undefined |
| 2019 | 44.3 M undefined | -340.7 M undefined | -320.6 M undefined |
| 2018 | 54.6 M undefined | -203.4 M undefined | -199.7 M undefined |
2Seventy Bio Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| REVENUE (M) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M) |
| NET INCOME (M) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 44 | 248 | 54 | 91 | 100 | 37 | 69 | 76 | 80 | 85 | 89 | 111 |
| - | -18.52 | 463.64 | -78.23 | 68.52 | 9.89 | -63.00 | 86.49 | 10.14 | 5.26 | 6.25 | 4.71 | 24.72 |
| 98.15 | 93.18 | 97.58 | 96.30 | 81.32 | 83.00 | 51.35 | 27.54 | 25.00 | 23.75 | 22.35 | 21.35 | 17.12 |
| 53 | 41 | 242 | 52 | 74 | 83 | 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| -199 | -320 | -120 | -292 | -254 | -217 | -57 | -24 | -12 | 14 | 21 | 31 | 47 |
| - | 60.80 | -62.50 | 143.33 | -13.01 | -14.57 | -73.73 | -57.89 | -50.00 | -216.67 | 50.00 | 47.62 | 51.61 |
| 23.4 | 23.4 | 23.4 | 23.5 | 35.6 | 49.28 | 52.22 | 0 | 0 | 0 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The 2Seventy Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the 2Seventy Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
2Seventy Bio stock margins
The 2Seventy Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 2Seventy Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 2Seventy Bio.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Gross margin
EBIT margin
Profit margin
Details
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the 2Seventy Bio's sales revenue. A higher gross margin percentage indicates that the 2Seventy Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the 2Seventy Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the 2Seventy Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the 2Seventy Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the 2Seventy Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the 2Seventy Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
2Seventy Bio Margin History
| 2Seventy Bio Gross margin | 2Seventy Bio Profit margin | 2Seventy Bio EBIT margin | 2Seventy Bio Profit margin |
|---|---|---|---|
| 2030e | 52.43 % | 0 % | 42.55 % |
| 2029e | 52.43 % | 5.59 % | 35.73 % |
| 2028e | 52.43 % | -8.08 % | 25.45 % |
| 2027e | 52.43 % | 0.16 % | 17.77 % |
| 2026e | 52.43 % | -16.31 % | -16.22 % |
| 2025e | 52.43 % | -46.73 % | -34.82 % |
| 2024 | 52.43 % | -260.35 % | -151.2 % |
| 2023 | 83.15 % | -216.1 % | -216.73 % |
| 2022 | 81.86 % | -277.05 % | -277.81 % |
| 2021 | 95.41 % | -557.43 % | -536.15 % |
| 2020 | 97.82 % | -55.7 % | -48.41 % |
| 2019 | 93.23 % | -769.07 % | -723.7 % |
| 2018 | 98.35 % | -372.53 % | -365.75 % |
2Seventy Bio Stock Sales Revenue, EBIT, Earnings per Share
The 2Seventy Bio earnings per share therefore indicates how much revenue 2Seventy Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Sales per Share
EBIT per share
Earnings per Share
Details
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue 2Seventy Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates 2Seventy Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of 2Seventy Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 2Seventy Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
2Seventy Bio Revenue, EBIT and net profit per share
| Date | 2Seventy Bio Sales per Share | 2Seventy Bio EBIT per share | 2Seventy Bio Earnings per Share |
|---|---|---|---|
| 2030e | 2.13 undefined | 0 undefined | 0.91 undefined |
| 2029e | 1.71 undefined | 0 undefined | 0.61 undefined |
| 2028e | 1.64 undefined | 0 undefined | 0.42 undefined |
| 2027e | 1.55 undefined | 0 undefined | 0.28 undefined |
| 2026e | 1.47 undefined | 0 undefined | -0.24 undefined |
| 2025e | 1.34 undefined | 0 undefined | -0.47 undefined |
| 2024 | 0.73 undefined | -1.89 undefined | -1.1 undefined |
| 2023 | 2.04 undefined | -4.4 undefined | -4.42 undefined |
| 2022 | 2.57 undefined | -7.12 undefined | -7.14 undefined |
| 2021 | 2.32 undefined | -12.93 undefined | -12.43 undefined |
| 2020 | 10.6 undefined | -5.91 undefined | -5.13 undefined |
| 2019 | 1.89 undefined | -14.56 undefined | -13.7 undefined |
| 2018 | 2.33 undefined | -8.69 undefined | -8.53 undefined |
2Seventy Bio business model
2Seventy Bio is one of the most popular companies on Eulerpool.com.
2Seventy Bio Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
2Seventy Bio historical P/E ratio, EBIT multiple, and P/S ratio
2Seventy Bio shares outstanding
The number of shares was 2Seventy Bio in 2024 — This indicates how many shares 52.218 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Number of stocks
Details
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue 2Seventy Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates 2Seventy Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of 2Seventy Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 2Seventy Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Unfortunately, there are currently no price targets and forecasts available for 2Seventy Bio.
2Seventy Bio latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 12/31/2024 | -0.27 | -0.37 (-36.88 %) | 2024 Q4 |
| 9/30/2024 | -0.25 | -0.19 (22.76 %) | 2024 Q3 |
| 6/30/2024 | -0.66 | 0.45 (168.1 %) | 2024 Q2 |
| 3/31/2024 | -0.83 | -1.01 (-21.92 %) | 2024 Q1 |
| 12/31/2023 | -1.01 | -1.11 (-9.91 %) | 2023 Q4 |
| 9/30/2023 | -1.05 | -1 (4.66 %) | 2023 Q3 |
| 6/30/2023 | -1.09 | -0.83 (23.59 %) | 2023 Q2 |
| 3/31/2023 | -1.22 | -1.08 (11.27 %) | 2023 Q1 |
| 12/31/2022 | -1.64 | -0.6 (63.37 %) | 2022 Q4 |
| 9/30/2022 | -1.84 | -1.76 (4.41 %) | 2022 Q3 |
1
2
Eulerpool ESG Scorecard© for the 2Seventy Bio stock
Eulerpool World ESG Rating (EESG©)
43/ 100
🌱 Environment
46
👫 Social
49
🏛️ Governance
34
Environment
Scope 1 - Direct Emissions | |
Scope 2 - Indirect emissions from purchased energy | |
Scope 3 - Indirect emissions within the value chain | |
Total CO₂ emissions | |
| CO₂ reduction strategy | |
| Coal energy | |
| Nuclear power | |
| Animal experiments | |
| Fur & Leather | |
| Pesticides | |
| Palm Oil | |
| Tobacco | |
| Genetically modified organisms | |
| Climate concept | |
| Sustainable forestry | |
| Recycling regulations | |
| Environmentally friendly packaging | |
| Hazardous substances | |
| Fuel consumption and efficiency | |
| Water consumption and efficiency |
Social
| Percentage of female employees | |
| Percentage of women in management | |
| Percentage of Asian employees | |
| Share of Asian management | |
| Percentage of Hispanic/Latino employees | |
| Hispano/Latino Management share | |
| Percentage of Black employees | |
| Black Management Share | |
| Percentage of white employees | |
| White Management Share | |
| Adult content | |
| Alcohol | |
| Weapons | |
| Firearms | |
| Gambling | |
| Military contracts | |
| Human rights concept | |
| Privacy concept | |
| Occupational health and safety | |
| Catholic |
Governance (Corporate Governance)
| Environmental reporting | |
| Stakeholder Engagement | |
| Call Back Policies | |
| Antitrust law |
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
2Seventy Bio shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 11.40186 % | Kynam Capital Management LP | 5,953,825 | 0 | 12/31/2024 |
| 8.18200 % | Goldman Sachs & Company, Inc. | 4,272,478 | 98,631 | 12/31/2024 |
| 7.29139 % | BlackRock Institutional Trust Company, N.A. | 3,807,417 | 344,443 | 12/31/2024 |
| 7.20297 % | The Vanguard Group, Inc. | 3,761,245 | -10,987 | 12/31/2024 |
| 5.26722 % | Morgan Stanley & Co. LLC | 2,750,437 | 38,221 | 12/31/2024 |
| 4.85433 % | Newtyn Management, LLC | 2,534,836 | -5,164 | 12/31/2024 |
| 4.81806 % | BofA Global Research (US) | 2,515,897 | 1,912,771 | 12/31/2024 |
| 4.78288 % | Baker Bros. Advisors LP | 2,497,526 | 0 | 12/31/2024 |
| 3.83010 % | Casdin Capital, LLC | 2,000,000 | 0 | 12/31/2024 |
| 2.40305 % | Regeneron Pharmaceuticals Inc | 1,254,827 | 1,254,827 | 12/31/2024 |
1
2
3
4
5
...
10
2Seventy Bio Executives and Management Board
Mr. Nick Leschly
(52)2Seventy Bio Chairman of the Board (since 2021)
Compensation 9.08 M
Mr. William Baird
(52)2Seventy Bio President, Chief Executive Officer, Director (since 2021)
Compensation 2.93 M
Dr. Wei Lin
(63)2Seventy Bio Independent Director
Compensation 622,048
Ms. Denice Torres
(64)2Seventy Bio Lead Independent Director
Compensation 304,002
Ms. Sarah Glickman
(55)2Seventy Bio Independent Director
Compensation 303,002
1
2
2Seventy Bio Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | 0,79 | 0,81 | 0,77 | 0,84 | |||
| SupplierCustomer | 0,65 | 0,69 | 0,25 | 0,86 | |||
| SupplierCustomer | 0,58 | 0,29 | 0,74 | -0,15 | |||
| SupplierCustomer | 0,50 | -0,25 | 0,10 | -0,74 | |||
| SupplierCustomer | 0,36 | 0,87 | 0,77 | 0,82 | |||
 Gritstone bio | SupplierCustomer | 0,07 | 0,88 | 0,45 | 0,92 | ||
| SupplierCustomer | 0,07 | 0,50 | 0,25 | 0,55 | |||
| SupplierCustomer | -0,03 | 0,81 | 0,67 | 0,94 | |||
 Novo Nordisk B | SupplierCustomer | -0,52 | 0,63 | 0,20 | -0,04 | ||
| SupplierCustomer | -0,62 | 0,46 | 0,61 | 0,07 |
1
Most common questions regarding 2Seventy Bio
What is the P/S ratio of 2Seventy Bio 2025?
The P/S cannot be calculated for 2Seventy Bio currently.
What is the Quality Investing of 2Seventy Bio?
The Quality Investing for 2Seventy Bio is 2/10.
What is the revenue of 2Seventy Bio 2025?
The expected 2Seventy Bio revenue is 69.85 M USD.
How high is the profit of 2Seventy Bio 2025?
The expected 2Seventy Bio profit is -24.32 M USD.
What is the business model of 2Seventy Bio
No history available for 2Seventy Bio.
What is the 2Seventy Bio dividend?
2Seventy Bio pays a dividend of 0 USD distributed over payouts per year.
How often does 2Seventy Bio pay dividends?
The dividend cannot currently be calculated for 2Seventy Bio or the company does not pay out a dividend.
What is the 2Seventy Bio ISIN?
The ISIN of 2Seventy Bio is US9013841070.
What is the 2Seventy Bio ticker?
The ticker of 2Seventy Bio is TSVT.
How much dividend does 2Seventy Bio pay?
Over the past 12 months, 2Seventy Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 2Seventy Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of 2Seventy Bio?
The current dividend yield of 2Seventy Bio is .
When does 2Seventy Bio pay dividends?
2Seventy Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of 2Seventy Bio?
2Seventy Bio paid dividends every year for the past 0 years.
What is the dividend of 2Seventy Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is 2Seventy Bio located?
2Seventy Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von 2Seventy Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of 2Seventy Bio from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did 2Seventy Bio pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of 2Seventy Bio in the year 2024?
In the year 2024, 2Seventy Bio distributed 0 USD as dividends.
In which currency does 2Seventy Bio pay out the dividend?
The dividends of 2Seventy Bio are distributed in USD.
2Seventy Bio stock
Sector
Health
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website 2Seventy Bio
Country
United States of America 🇺🇸
Currency
USD
Initial public offering
Oct 18, 2021
ISIN
US9013841070
GOSIN
Global Open Securities Identification Number
Cusip
901384107
Market capitalization
Quality Investing
2 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2Seventy Bio Peer Group
2Seventy Bio Eulerpool News
2Seventy Bio News
2Seventy Bio Ticker
| Stock Exchange | 2Seventy Bio Ticker |
|---|---|
| NASDAQ | TSVT |
2Seventy Bio FIGI
| 2Seventy Bio Ticker | 2Seventy Bio FIGI |
|---|---|
| TSVT:US | BBG00YV1J622 |
| TSVT:UA | BBG01315V7T8 |
| TSVT:UC | BBG01315V7V5 |
| TSVT:UN | BBG01315V7X3 |
| TSVT:UP | BBG01315V7Y2 |
| TSVT:UB | BBG01315V807 |
| TSVT:UM | BBG01315V825 |
| TSVT:UX | BBG01315V843 |
| TSVT:UD | BBG01315V8B5 |
| TSVT:UW | BBG01315V8D3 |
| TSVT:UF | BBG01315V8F1 |
| TSVT:VY | BBG01315V8G0 |
| TSVT:VJ | BBG01315V8H9 |
| TSVT:VK | BBG01315V8J7 |
| TSVT:VF | BBG01315V8K5 |
| TSVT*:MM | BBG013DRGN55 |
| TSVT*:MF | BBG013DRGN64 |
| TSVT*:MU | BBG013DRGN73 |
| TSVT-RM:RM | BBG013TS6LV2 |
| TSVT-RM:RX | BBG013TS6LW1 |
| TSVT-RM:RN | BBG013TS6LX0 |
| TSVT-RM:RP | BBG013TS6LY9 |
All fundamentals about 2Seventy Bio
Our stock analysis for 2Seventy Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 2Seventy Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
2Seventy Bio Revenue- 2Seventy Bio Net Income
- 2Seventy Bio P/E
- 2Seventy Bio P/S
- 2Seventy Bio EBIT
- 2Seventy Bio Dividend
- 2Seventy Bio Stocks
- 2Seventy Bio Market capitalization
- 2Seventy Bio Debt
- 2Seventy Bio Liabilities
- 2Seventy Bio Equity
- 2Seventy Bio AAQS
- 2Seventy Bio Employees
- 2Seventy Bio ROE
- 2Seventy Bio ROA
- 2Seventy Bio ROCE